Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Vanessa B Vogensen"'
Autor:
Vanessa B. Vogensen, Richard M. Anthony, Huib A.M. Kerstjens, Simon Tiberi, Jurriaan E.M. de Steenwinkel, Onno W. Akkerman
Publikováno v:
Clinical Microbiology and Infection, 28(8), 1047-1049. ELSEVIER SCI LTD
Clinical Microbiology and Infection, 28(8), 1047-1049. Elsevier Ltd.
Clinical Microbiology and Infection, 28(8), 1047-1049. Elsevier Ltd.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e6ae1c2d03f3323bb06cff99e57f831
https://doi.org/10.1016/j.cmi.2022.03.033
https://doi.org/10.1016/j.cmi.2022.03.033
Autor:
Tjip S. van der Werf, Dick van Soolingen, Marieke G G Sturkenboom, Onno W. Akkerman, Richard M. Anthony, Wiel C M de Lange, Mathieu S. Bolhuis, Vanessa B Vogensen, Huib A. M. Kerstjens, Jan-Willem C. Alffenaar
Publikováno v:
Antimicrobial Agents and Chemotherapy, 66(2):e01829-21. AMER SOC MICROBIOLOGY
Antimicrob Agents Chemother
Antimicrob Agents Chemother
Moxifloxacin is an attractive drug for the treatment of isoniazid-resistant rifampicin-susceptible tuberculosis (TB) or drug-susceptible TB complicated by isoniazid intolerance. However, co-administration with rifampicin decreases moxifloxacin exposu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15a9f9ff8a8cc9d29e04b52704049c4b
https://research.rug.nl/en/publications/19364a90-b913-4be9-a073-401e4b3a043b
https://research.rug.nl/en/publications/19364a90-b913-4be9-a073-401e4b3a043b
